This study will evaluate the anti-tumor response, as well as possible changes of IFN-γ and IL-12 levels in blood comparing to the baseline and changes of immune cell distribution in tumor tissue after GX-051 intratumoral injection (NCT02079324 ClinicalTrials.gov). This evidence concerns the gene IFNG and neoplasm.